Hyperuricemia in patients with newly detected MDR tuberculosis

<b>Aim:</b> to study of changes in serum uric acid levels in patients with newly diagnosed MDR pulmonary tuberculosis (TB) before and during treatment with pyrazinamide. <b>Materials and Methods:</b> we studied the level of uric acid (UA) in sera of 134 patients (78 men and 56 women). The study was carried before and after 1,2,3,4,5,6,7 and 8 months of treatment (intensive phase). <b>Results:</b> It was found that the level of UA before the treatment increased and significantly higher than normal values in 28,2% men and in 37,5% women. After 1 month of chemotherapy in these patients the level of UA continues to grow and significantly exceeds the initial values. Starting from the 2nd month of treatment, the concentration of UA decreases. Primary cases of an increase in UA levels in patients with initially normal values were observed every month the entire period of treatment, both in men and women. Moreover, in men, hyperuremia was more often observed during the first 2 months of treatment (23,2% and 10,7%). Starting from the 3rd month, the number of patients with a primary increase in UA levels at different periods of treatment ranged from 3,6 to 7,1%. In women, hyperuricemia was also more often observed in the first 2 months of treatment (22,8% and 20,0%). From the 3rd to 5th months of chemotherapy, new cases of an increase in the level of UA were observed in 5,7% of patients. Starting from the 6th month of treatment, an increase in the number of such patients was again observed. In 37,5% of men and in 8,6% of women, before and during the treatment, the level of UA was normal. <b>Conclusion:</b> Uric acid levels must be determined before and within 8 months of treating patients with newly diagnosed MDR TB.